. 2018 Nov 2;119(10):1244–1251. doi: 10.1038/s41416-018-0230-7

Table 1.

Summary of patient characteristics

Feature		CAIRO	LUMC	CAIRO2	AMC-AJCCII-90
No. of patients		504	270	472	76
Sample information	TMA or slide	TMA	TMA	TMA	Whole slide
	Core diameter	2 mm	0.6 mm	2 mm	–
	Staining	CK	CK	CK	H&E
Age (years)		62.8 (41–78)	65.4 (39.3–86.4)	61.3 (40.3–76)	–
Sex	F	181	135	197	40
Sex	M	322	135	275	36
Stage	1	0	43	0	0
	2	0	99	0	76
	3	0	75	0	0
	4	504	50	472	0
Event status	None	61	91	104	60
Event status	Yes	443	179	368	16
Treatment arm^a	A	252	–	243	–
Treatment arm^a	B	252	–	229	–
Mutational information
MSI	MSI-H	12	29	8	23
MSI	MSS/MSI-L	423	189	464	53
KRAS/BRAF	mut	174	–	218	31
KRAS/BRAF	wt	139	–	227	45
CMS classification
CMS classifier		IHC	IHC	IHC	GeneExp
CMS available		401	214	340	76
Subtype	CMS2/3	247	96	162	35
Subtype	CMS4	142	89	170	15

TMA tissue microarray, CK pan-cytokeratin, H&E haematoxylin and eosin, MSI microsatellite instability, CMS Consensus Molecular Subtype

^aTreatment arms: CAIRO—sequential (Arm A) versus combination (Arm B) capecitabine, irinotecan, and oxaliplatin. CAIRO2—capecitabine, oxaliplatin, and bevacizumab (Arm A) with cetuximab (Arm B)